| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Pires, Marcelo A., et al.
(författare)
-
Probing fractal spatiotemporal inhomogeneity in a quantum walk
- 2024
-
Ingår i: Physical Review A: covering atomic, molecular, and optical physics and quantum information. - 2469-9926 .- 2469-9934. ; 109:2
-
Tidskriftsartikel (refereegranskat)abstract
- We investigate the transport and entanglement properties exhibited by quantum walks with coin operators concatenated in a space-time fractal structure. Inspired by recent developments in photonics, we choose the paradigmatic Sierpinski gasket. The 0-1 pattern of the fractal is mapped into an alternation of the generalized Hadamard-Fourier operators. This two-state coin-operator approach overcomes the intricacies caused by the utilization of high-dimensional coin operators required in prior studies of discrete-time quantum walks on fractals. In fulfilling the blank space on the analysis of the impact of inhomogeneity in quantum walk properties, specifically, fractal deterministic inhomogeneity, our results show a robust effect of entanglement enhancement as well as an interesting road to superdiffusive spreading with a tunable scaling exponent attaining robust superdiffusion, subballistic though. Explicitly, with this fractal approach it is possible to obtain an increase in quantum entanglement with reduced impact on standard quantum walk theoretical spreading. Alongside those features, we analyze further properties such as the degree of interference and visibility. The present model corresponds to an application of fractals in an experimentally viable setting, namely, the building block for the construction of photonic patterned structures.
|
|
| 9. |
- Teixo, R, et al.
(författare)
-
Application of Perinatal Derivatives on Oncological Preclinical Models: A Review of Animal Studies
- 2022
-
Ingår i: International journal of molecular sciences. - : MDPI AG. - 1422-0067. ; 23:15
-
Tidskriftsartikel (refereegranskat)abstract
- The increasing cancer incidence has certified oncological management as one of the most critical challenges for the coming decades. New anticancer strategies are still needed, despite the significant advances brought to the forefront in the last decades. The most recent, promising therapeutic approaches have benefitted from the application of human perinatal derivatives (PnD), biological mediators with proven benefits in several fields beyond oncology. To elucidate preclinical results and clinic outcomes achieved in the oncological field, we present a narrative review of the studies resorting to animal models to assess specific outcomes of PnD products. Recent preclinical evidence points to promising anticancer effects offered by PnD mediators isolated from the placenta, amniotic membrane, amniotic fluid, and umbilical cord. Described effects include tumorigenesis prevention, uncontrolled growth or regrowth inhibition, tumor homing ability, and adequate cell-based delivery capacity. Furthermore, PnD treatments have been described as supportive of chemotherapy and radiological therapies, particularly when resistance has been reported. However, opposite effects of PnD products have also been observed, offering support and trophic effect to malignant cells. Such paradoxical and dichotomous roles need to be intensively investigated. Current hypotheses identify as explanatory some critical factors, such as the type of the PnD biological products used or the manufacturing procedure to prepare the tissue/cellular treatment, the experimental design (including human-relevant animal models), and intrinsic pathophysiological characteristics. The effective and safe translation of PnD treatments to clinical practice relies on the collaborative efforts of all researchers working with human-relevant oncological preclinical models. However, it requires proper guidelines and consensus compiled by experts and health workers who accurately describe the methodology of tissue collection, PnD isolation, manufacturing, preservation, and delivery to the final user.
|
|
